Ascend amlodipine and olmesartan tablets failed dissolution specifications
Amlodipine and Olmesartan Medoxomil Tablets, 5 mg/40 mg, are being recalled after failing dissolution specifications, with olmesartan medoxomil content below specification.
What this means for you
Real risk of harm even if no illness or injury has been reported yet. Stop using the product and follow the agency's guidance.
Our severity reasoning: FDA Class II recall for a failed dissolution specification with active ingredient below specification, a risk of harm with no injuries reported.
Plain-English summary
Amlodipine and Olmesartan Medoxomil Tablets, 5 mg/40 mg, in 30-count bottles, manufactured by Alkem Laboratories Ltd. in India and distributed by Ascend Laboratories, LLC of Parsippany, New Jersey, NDC 67877-501-30, are being recalled. The action covers 15,696 bottles of 30.
The stated reason is failed dissolution specifications, with olmesartan medoxomil content below specifications. Dissolution testing measures how a tablet releases its active ingredient. The FDA classified the action as Class II.
The affected lot is 24123460, expiring 31 October 2027. Distribution was USA nationwide.
This is a prescription blood pressure medicine. Patients should not stop taking a prescribed course without medical advice; anyone holding the affected lot should contact their pharmacy or prescriber about a replacement supply.
The recalled product
- Product
- AMLODIPINE AND OLMESARTAN MEDOXOMIL (AMLODIPINE AND OLMESARTAN MEDOXOMIL)
- Brand
- AMLODIPINE AND OLMESARTAN MEDOXOMIL
- Manufacturer
- Ascend Laboratories, LLC
- Category
- Drug — Antihypertensive tablet
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (3)
- Lot: 24123460
- Expires: October 31
- 2027.
Distribution
Distributed nationwide across the United States.
Related recalls
Same brand · AMLODIPINE AND OLMESARTAN MEDOXOMIL
- ModerateFDA Recalls Amlodipine and Olmesartan Tablets Over Failed Dissolution Test
FDA (Drugs) · 2026-07-29
- HighAmlodipine and olmesartan tablets recalled after failing dissolution specification testing
FDA (Drugs) · 2025-08-20
- ModerateAmlodipine and Olmesartan Medoxomil Tablets Recalled for cGMP Deviations
FDA (Drugs) · 2022-03-09
- Moderate
- LowAurobindo Recalls Amlodipine and Olmesartan Medoxomil Tablets Due to Discoloration
FDA (Drugs) · 2018-12-12
Same manufacturer · Ascend Laboratories, LLC
See all →- LowDabigatran Etexilate Capsules Recalled Due to Impurity Specification Failure
FDA (Drugs) · 2026-08-05
- LowDabigatran Etexilate Capsules Recalled Over Impurity Specification Failure
FDA (Drugs) · 2026-08-05
- LowDabigatran Etexilate Capsules Recalled Due to Impurity Specification Failure
FDA (Drugs) · 2026-08-05
- ModerateDabigatran Etexilate Capsules Recalled Over Impurity Test Failure
FDA (Drugs) · 2026-07-29
- ModerateDrug Recall: Dabigatran Etexilate Capsules 150 mg by Ascend Laboratories
FDA (Drugs) · 2026-07-29
Same hazard · failed dissolution
See all →- ModerateNovartis Recalls Diovan Valsartan Tablets Due to Failed Dissolution Specifications
FDA (Drugs) · 2026-08-19
- LowSupernus Recalls Trokendi XR Capsules for Failed Dissolution Specifications
FDA (Drugs) · 2026-07-29
- HighLannett niacin extended-release tablets failed dissolution specifications during stability
FDA (Drugs) · 2026-06-10
- HighMajor Pharmaceuticals memantine extended-release capsules fail dissolution specifications
FDA (Drugs) · 2026-04-22
- HighXanax XR 3 mg extended-release tablets fail dissolution specifications
FDA (Drugs) · 2026-04-15